{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:50:07Z","timestamp":1789059007902,"version":"build-2803163510"},"reference-count":88,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordination for the improvement of Higher Education Personnel","doi-asserted-by":"publisher","award":["88881.310737\/2018-01"],"award-info":[{"award-number":["88881.310737\/2018-01"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["308524\/2022-5"],"award-info":[{"award-number":["308524\/2022-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.drudis.2025.104455","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T23:33:25Z","timestamp":1755128005000},"page":"104455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Galectins in inflammatory skin diseases: current roles and future directions"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3015-6295","authenticated-orcid":false,"given":"Mab P.","family":"Corr\u00eaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9533-9781","authenticated-orcid":false,"given":"Rebeca D.","family":"Correia-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1796-9577","authenticated-orcid":false,"given":"Diego D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-7650","authenticated-orcid":false,"given":"Karin V.","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6979-4126","authenticated-orcid":false,"given":"Cristiane D.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104455_b0005","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1002\/pmic.201600116","article-title":"Key regulators of galectin-glycan interactions","volume":"16","author":"Kamili","year":"2016","journal-title":"Proteomics"},{"key":"10.1016\/j.drudis.2025.104455_b0010","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/ijms19020392","article-title":"Dissecting the structure-activity relationship of galectin-ligand interactions","volume":"19","author":"Chan","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104455_b0015","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.208884","article-title":"Galectins at a glance","volume":"131","author":"Johannes","year":"2018","journal-title":"J Cell Sci"},{"key":"10.1016\/j.drudis.2025.104455_b0020","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1074\/jbc.270.10.5207","article-title":"Galectin-1, a beta-galactoside-binding lectin in Chinese hamster ovary cells. II. Localization and biosynthesis","volume":"270","author":"Cho","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104455_b0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fimmu.2012.00199","article-title":"Galectins as self\/non-self recognition receptors in innate and adaptive immunity: an unresolved paradox","volume":"3","author":"Vasta","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0030","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.3389\/fimmu.2018.02839","article-title":"Galectin-glycan interactions as regulators of B cell immunity","volume":"9","author":"Giovannone","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/exd.13512","article-title":"The expression and function of galectins in skin physiology and pathology","volume":"27","author":"Wu","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.steroids.2015.04.006","article-title":"On the role of skin in the regulation of local and systemic steroidogenic activities","volume":"103","author":"Slominski","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/j.drudis.2025.104455_b0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tox.2017.06.008","article-title":"Quantitative structure-skin permeability relationships","volume":"387","author":"Tsakovska","year":"2017","journal-title":"Toxicology"},{"key":"10.1016\/j.drudis.2025.104455_b0050","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.3390\/ijms20081811","article-title":"The dynamics of the skin's immune system","volume":"20","author":"Nguyen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104455_b0055","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/cei.13575","article-title":"Keratinocytes: innate immune cells in atopic dermatitis","volume":"204","author":"Chieosilapatham","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-018-0084-5","article-title":"The immunological anatomy of the skin","volume":"19","author":"Kabashima","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0065","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/exd.12832","article-title":"The dynamic anatomy and patterning of skin","volume":"25","author":"Wong","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0070","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri2622","article-title":"Skin immune sentinels in health and disease","volume":"9","author":"Nestle","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00304505","article-title":"Expression of the endogenous 14-kDa beta-galactoside-binding lectin galectin in normal human skin","volume":"280","author":"Akimoto","year":"1995","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.drudis.2025.104455_b0080","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdermsci.2011.07.008","article-title":"Galectin-3 and the skin","volume":"64","author":"Larsen","year":"2011","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.drudis.2025.104455_b0085","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/JID.2015.366","article-title":"Galectin-7 regulates keratinocyte proliferation and differentiation through JNK-miR-203-p63 signaling","volume":"136","author":"Chen","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0090","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/cells10040947","article-title":"The role of galectin-9 as mediator of atopic dermatitis: effect on keratinocytes","volume":"10","author":"Corr\u00eaa","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2025.104455_b0095","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaci.2011.01.053","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2013part I: clinical and pathologic concepts","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/exd.13336","article-title":"Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment","volume":"27","author":"Guttman-Yassky","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0105","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.clindermatol.2018.05.007","article-title":"Epidemiology of adult atopic dermatitis","volume":"36","author":"Sacotte","year":"2018","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?","volume":"48","author":"Guttman-Yassky","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0115","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41590-018-0256-2","article-title":"The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis","volume":"19","author":"Dainichi","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0120","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.3390\/ijms22137227","article-title":"The implications of pruritogens in the pathogenesis of atopic dermatitis","volume":"22","author":"Wong","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104455_b0125","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jid.2021.05.033","article-title":"Nuclear IL-33 plays an important role in IL-31\u2013mediated downregulation of FLG, Keratin 1, and Keratin 10 by regulating signal transducer and activator of transcription 3 activation in human keratinocytes","volume":"142","author":"Dai","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0130","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/pai.12331","article-title":"Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants","volume":"26","author":"Luger","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0135","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jaad.2005.03.013","article-title":"Etanercept is minimally effective in 2 children with atopic dermatitis","volume":"53","author":"Buka","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0140","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaad.2004.11.022","article-title":"Infliximab in the treatment of moderate to severe atopic dermatitis","volume":"52","author":"Jacobi","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0145","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.drudis.2025.104455_b0150","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s10753-021-01608-7","article-title":"Expression pattern and immunoregulatory roles of Galectin-1 and Galectin-3 in atopic dermatitis and psoriasis","volume":"45","author":"Corr\u00eaa","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.drudis.2025.104455_b0155","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00109-017-1566-9","article-title":"Anti-inflammatory effect of galectin-1 in a murine model of atopic dermatitis","volume":"95","author":"Corr\u00eaa","year":"2017","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.drudis.2025.104455_b0160","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000059408","article-title":"Enhancement of IgE production in B cells by neutrophils via galectin-3 in IgE-associated atopic eczema\/dermatitis syndrome","volume":"128","author":"Kimata","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0165","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2353\/ajpath.2009.080500","article-title":"Galectin-3 is critical for the development of the allergic inflammatory response in a mouse model of atopic dermatitis","volume":"174","author":"Saegusa","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2025.104455_b0170","first-page":"8302","article-title":"CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis","volume":"63","author":"Fukumori","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104455_b0175","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1158\/0008-5472.CAN-04-0336","article-title":"Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways","volume":"64","author":"Fukumori","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104455_b0180","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/cea.13672","article-title":"Protective role of Galectin-7 for skin barrier impairment in atopic dermatitis","volume":"50","author":"Umayahara","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.drudis.2025.104455_b0185","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3390\/medicina61050926","article-title":"Clinical effectiveness, clinical stability, and effects on serum Galectin-7 levels of dupilumab and JAK inhibitors in moderate-to-severe atopic dermatitis: a real-world, single-center analysis","volume":"61","author":"Horie","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.drudis.2025.104455_b0190","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/ics.12326","article-title":"Galectin-7 in the stratum corneum: a biomarker of the skin barrier function","volume":"38","author":"Niiyama","year":"2016","journal-title":"Int J Cosmet Sci"},{"key":"10.1016\/j.drudis.2025.104455_b0195","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1346-8138.12884","article-title":"Elevated serum galectin-9 levels in patients with atopic dermatitis","volume":"42","author":"Nakajima","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/CCID.S229393","article-title":"Role of Galectin-9 in atopic dermatitis \u2013 is it mediated through E selectin? A clinical and immunohistochemical study","volume":"13","author":"Farag","year":"2020","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0205","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clim.2009.04.012","article-title":"Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and\/or Th17-mediated skin inflammation","volume":"132","author":"Niwa","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0210","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1365-2133.2005.06508.x","article-title":"Interferon (IFN)-gamma is a main mediator of keratinocyte (HaCaT) apoptosis and contributes to autocrine IFN-gamma and tumour necrosis factor-alpha production","volume":"152","author":"Konur","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0215","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1398-9995.2006.01130.x","article-title":"Regulatory mechanisms of galectin-9 and eotaxin-3 synthesis in epidermal keratinocytes: possible involvement of galectin-9 in dermal eosinophilia of Th1-polarized skin inflammation","volume":"61","author":"Igawa","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.drudis.2025.104455_b0220","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.3389\/fimmu.2019.03063","article-title":"Galectin-9 Induced by dietary probiotic mixture regulates immune balance to reduce atopic dermatitis symptoms in mice","volume":"10","author":"Kim","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0225","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4014\/jmb.2005.05017","article-title":"Galectin-9 induced by dietary prebiotics regulates immunomodulation to reduce atopic dermatitis symptoms in 1-chloro-2,4-dinitrobenzene (DNCB)-treated NC\/Nga mice","volume":"30","author":"Kim","year":"2020","journal-title":"J Microbiol Biotechnol"},{"key":"10.1016\/j.drudis.2025.104455_b0230","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/JID.2015.369","article-title":"Elevated Galectin-10 expression of IL-22-producing T cells in patients with atopic dermatitis","volume":"136","author":"Noh","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0235","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.3390\/ijms22094983","article-title":"Psoriasis: from pathogenesis to pharmacological and nano-technological-based therapeutics","volume":"22","author":"Petit","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104455_b0240","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/ijms19010179","article-title":"Scanning the immunopathogenesis of psoriasis","volume":"19","author":"Chiricozzi","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104455_b0245","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/abd1806-4841.20153038","article-title":"Psoriasis: classical and emerging comorbidities","volume":"90","author":"MeF","year":"2015","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0250","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104455_b0255","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/ijms19010171","article-title":"Psoriasis: a STAT3-centric view","volume":"19","author":"Calautti","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104455_b0260","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2014.11.015","article-title":"The translational revolution and use of biologics in patients with inflammatory skin diseases","volume":"135","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0265","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113388","article-title":"Current therapeutic overview and future perspectives regarding the treatment of psoriasis","volume":"143","author":"Ferrara","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2025.104455_b0275","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/path.3996","article-title":"Psoriasis in humans is associated with down-regulation of galectins in dendritic cells","volume":"228","author":"de la Fuente","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.drudis.2025.104455_b0280","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3390\/biom13101472","article-title":"Evaluation of plasma concentrations of Galectins-1, 2 and 12 in psoriasis and their clinical implications","volume":"13","author":"Nowowiejska","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2025.104455_b0285","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jaut.2017.11.002","article-title":"Decrease of galectin-3 in keratinocytes: a potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis","volume":"89","author":"Shi","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.drudis.2025.104455_b0290","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/09546634.2019.1670778","article-title":"Evaluation of Galectin3 levels in psoriatic patients treated by narrow-band UVB phototherapy","volume":"31","author":"Khater","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.drudis.2025.104455_b0295","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14545","article-title":"Serum galectin-3 levels in patients with psoriasis","volume":"75","author":"Hayran","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.drudis.2025.104455_b0300","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/08923973.2023.2229510","article-title":"TNF-\u03b1 promotes CXCL-1\/8 production in keratinocytes by downregulating galectin-3 through NF-\u03baB and hsa-miR-27a-3p pathway to contribute psoriasis development","volume":"45","author":"Qiu","year":"2023","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.drudis.2025.104455_b0305","doi-asserted-by":"crossref","DOI":"10.1172\/JCI130740","article-title":"Galectin-7 downregulation in lesional keratinocytes contributes to enhanced IL-17A signaling and skin pathology in psoriasis","volume":"131","author":"Chen","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104455_b0310","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jaci.2012.06.044","article-title":"Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation","volume":"130","author":"Choy","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0315","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jid.2020.07.021","article-title":"Galectin-8 is upregulated in keratinocytes by IL-17A and promotes proliferation by regulating mitosis in psoriasis","volume":"141","author":"Lo","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0320","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/ijdvl.IJDVL_252_18","article-title":"Serum galectin-9 levels in atopic dermatitis, psoriasis and allergic contact dermatitis: a cross-sectional study","volume":"85","author":"Nofal","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.drudis.2025.104455_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2023.110741","article-title":"The elevation of plasma galectin-9 levels in patients with psoriasis and its associations with inflammatory and immune checkpoint molecules in skin tissues","volume":"85","author":"Chagan-Yasutan","year":"2024","journal-title":"Hum Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0330","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clim.2008.01.006","article-title":"Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis","volume":"127","author":"Seki","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104455_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114513","article-title":"The mechano-chemical circuit in fibroblasts and dendritic cells drives basal cell proliferation in psoriasis","volume":"43","author":"Jiang","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2025.104455_b0340","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0961203317736144","article-title":"The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients","volume":"27","author":"Shi","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.drudis.2025.104455_b0345","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/art.38891","article-title":"Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus","volume":"67","author":"Shi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.drudis.2025.104455_b0350","doi-asserted-by":"crossref","first-page":"15319","DOI":"10.3390\/ijms232315319","article-title":"Increased expression of Galectin-3 in skin fibrosis: evidence from in vitro and in vivo studies","volume":"23","author":"Peir\u00f3","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104455_b0355","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/RHU.0000000000001367","article-title":"Galectin-1 and Galectin-3 expression in lesional skin of patients with systemic sclerosis-association with disease severity","volume":"27","author":"Mora","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.drudis.2025.104455_b0360","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.650605","article-title":"Circulating Galectin-1 and Galectin-3 in sera from patients with systemic sclerosis: associations with clinical features and treatment","volume":"12","author":"Sundblad","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104455_b0365","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jid.2017.04.035","article-title":"Systemic sclerosis dermal fibroblasts suppress Th1 cytokine production via Galectin-9 overproduction due to Fli1 deficiency","volume":"137","author":"Saigusa","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0370","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/exd.13900","article-title":"A potential contribution of decreased galectin-7 expression in stratified epithelia to the development of cutaneous and oesophageal manifestations in systemic sclerosis","volume":"28","author":"Saigusa","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.drudis.2025.104455_b0375","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/art.40881","article-title":"Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation","volume":"71","author":"Wienke","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.drudis.2025.104455_b0380","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.38676","article-title":"Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis","volume":"66","author":"Bellutti Enders","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.drudis.2025.104455_b0385","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-1-0716-2055-7_12","article-title":"Dissecting context-specific galectin binding using glycoengineered cell libraries","volume":"2442","author":"Nielsen","year":"2022","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2025.104455_b0390","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-0716-2055-7_9","article-title":"Examining galectin binding specificity using glycan microarrays","volume":"2442","author":"Stowell","year":"2022","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2025.104455_b0395","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/978-1-0716-2055-7_16","article-title":"Investigation of galectins in frozen tissue and mammalian cell culture using confocal miccroscopy","volume":"2442","author":"Cerri","year":"2022","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2025.104455_b0400","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-1-0716-2055-7_17","article-title":"Exploring the galectin network by light and fluorescence microscopy","volume":"2442","author":"Garc\u00eda Caballero","year":"2022","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2025.104455_b0405","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/978-1-0716-2055-7_24","article-title":"Examining galectin gene regulation by reporter assays","volume":"2442","author":"Schmidt","year":"2022","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2025.104455_b0410","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.3390\/molecules24244554","article-title":"3-Substituted 1-naphthamidomethyl-C-galactosyls interact with two unique sub-sites for high-affinity and high-selectivity inhibition of Galectin-3","volume":"24","author":"Dahlqvist","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2025.104455_b0415","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1021\/acsmedchemlett.3c00261","article-title":"Discovery of N-arylsulfonyl-Indole-2-carboxamide derivatives as Galectin-3 and Galectin-8 C-terminal domain inhibitors","volume":"14","author":"Zhang","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2025.104455_b0420","doi-asserted-by":"crossref","unstructured":"Herman KD, et al. Pharmacological characterization of GB1908, a selective Galectin-1 carbohydrate binding domain inhibitor for the treatment of cancer. Pharmacology. Published online February 3, 2025. https:\/\/doi.org\/10.1159\/000543234.","DOI":"10.1159\/000543234"},{"key":"10.1016\/j.drudis.2025.104455_b0425","doi-asserted-by":"crossref","unstructured":"Chen Y, et al. Dupilumab-induced inhibition of myeloid dendritic cell function via TIM-3-TGF-\u03b21 feedback loop in treatment of atopic dermatitis. J Allergy Clin Immunol. Published online May 8, 2025. https:\/\/doi.org\/10.1016\/j.jaci.2025.05.001.","DOI":"10.1016\/j.jaci.2025.05.001"},{"key":"10.1016\/j.drudis.2025.104455_b0430","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10439-022-02949-6","article-title":"Experimental and computational models of transport of Galectin-3 through glycosylated matrix","volume":"50","author":"Pi\u00f1eiro-Llanes","year":"2022","journal-title":"Ann Biomed Eng"},{"key":"10.1016\/j.drudis.2025.104455_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101308","article-title":"Perturbing dimer interactions and allosteric communication modulates the immunosuppressive activity of human galectin-7","volume":"297","author":"Pham","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104455_b0440","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jprot.2013.12.017","article-title":"Transcriptional and proteomic analysis reveal recombinant galectins of Haemonchus contortus down-regulated functions of goat PBMC and modulation of several signaling cascades in vitro","volume":"98","author":"Wang","year":"2014","journal-title":"J Proteomics"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:55:10Z","timestamp":1772884510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625001680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":88,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1359644625001680"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104455","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galectins in inflammatory skin diseases: current roles and future directions","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104455"}}